GlassScriptPhysician profile
Wei Zhang
NPI 1669813242
$22,272.28
in general payments reported to CMS, 2019-2025
13 companies · $18K in 2025
The $18K reported for 2025 was more than what 91% of Clinical Pathology/Laboratory Medicine providers received nationally (typical 2025 total: $114).
See the full distribution for Clinical Pathology/Laboratory Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $1,365 · 2023: $251 · 2024: $2,630 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $1,477 · Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,270.00 |
| Travel and Lodging | $1,477.24 |
| Food and Beverage | $1,035.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $16,131.27 | 2024-2025 | |
| Gilead Sciences, INC. | $2,504.68 | 2025 | |
| Eli Lilly and Company | $1,400.00 | 2025 | |
| Incyte Corporation | $1,365.00 | 2020 | |
| Illumina, INC. | $201.03 | 2023 | Oncology Testing |
| Syndax Pharmaceuticals, INC. | $125.26 | 2025 | Revuforj |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $121.87 | 2024 | Libtayo |
| Labcorp Holdings INC. | $113.00 | 2024 | Pgdx Elio Tissue Complete |
| Tg Therapeutics, INC. | $108.63 | 2023-2025 | |
| Lilly USA, LLC | $29.85 | 2023 | |
| Abbott Laboratories | $27.20 | 2024 | Alinity |
| Pfizer INC. | $19.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.